Hunter, Deborah S.

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

Harrison, C., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L., et al. (2012) · New England Journal of Medicine

Myeloproliferative Neoplasms: Diagnosis and TreatmentAcute Myeloid Leukemia Research

Cited by 1,825

CCR2 modulates inflammatory and metabolic effects of high-fat feeding

Weisberg, S. P., Hunter, D., Huber, R., Lemieux, J., Slaymaker, S., Vaddi, K., Charo, I., Leibel, R. L., & Jr., A. W. F. (2006) · Journal of Clinical Investigation

Adipokines, Inflammation, and Metabolic DiseasesAdipose Tissue and Metabolism

Cited by 1,497

Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy

Harrison, C. N., Mesa, R. A., Kiladjian, J., Al‐Ali, H., Gisslinger, H., Knoops, L., Squier, M., Sirulnik, A., Mendelson, E., Zhou, X., et al. (2013) · British Journal of Haematology

Myeloproliferative Neoplasms: Diagnosis and TreatmentAcute Myeloid Leukemia Research

Cited by 90